Scientists at Wake Forests School Of Medicine,North Carolina, conducted a therapeutic study of the effects of using non-thermal radio waves on liver cancer cells. The study concluded that the new targeted therapy has proven to be successful in blocking the growth of liver cancer cells anywhere in the body without damaging healthy cells
The research team headed by Boris Pasche, M.D., Ph.D., chair of cancer biology and director of the Cancer Center at Wake Forest Baptist, delivered levels of radio frequencies to animal models that had beenpreviously injected with human cancer cells to replicate hepatocellular carcinoma (HCC), a prevailing form liver cancer.
The radio frequencies were the same as those delivered to patients with HCC in Europe where the device has been approved for use in humans."Our study showed that the radiofrequency delivered was at low and safe levels to humans," Pasche said in an interview with Thailand Medical News via skype "It was actually lower than those generated by holding a mobile phone close to the ear."
The devices that was used in the studies were invented by Pasche and Alexandre Barbault, of TheraBionic Inc, that delivered cancer-specific, amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) programmed specifically for Hepatocellular Carcinoma. The AM RF EMF activated a calcium channel on the surface of HCC tumor cells but not on noncancerous cells.
It was observed that a specific calcium channel, Cav3.2, was behaving like an antenna for the radio signals that were sent out, which allowed calcium to penetrate the HCC cell membrane and go into the cell, triggering HCC growth blockage and reversals.
It was found that the influx of calcium stopped the growth of HCC cells and cause it to shrink and in some cases even eliminated the tumors. The effect was the same for cancers that had metastasized to other parts of the body. The team plans to further study and identify the exact signaling cascade within the tumor cell that leads to the anti-cancer effects.
The device, which is licensed to TheraBionic Inc.,been approved by the European Notified Body,(EU FDA). It is under review by the US FDA. The treatment, which is approved for use in patients in Europe, consists of a hand-held device about the size of a VHS tape cassette that emits radio frequencies via a spoon-shaped element that is placed on the patient's tongue. The treatment is administered at the patient's residence three times a day for one hour. The frequencies used are specific to the patient's type of cancer as identified through tumor biopsies or blood work.
The findings of the study were published in the online edition of the journal EBioMedicine
, a Lancet publication. A further positive study, also using the same technology with breast cancer cells was also published in the same journal.
Pasche and Barbault have jointly discovered specific radio frequencies act on 15 different types of cancer, as previously reported in a study published in 2009 in the Journal of Experimental & Clinical Cancer Research